These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1187 related items for PubMed ID: 25378643

  • 21. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
    Schutsky K, Song DG, Lynn R, Smith JB, Poussin M, Figini M, Zhao Y, Powell DJ.
    Oncotarget; 2015 Oct 06; 6(30):28911-28. PubMed ID: 26359629
    [Abstract] [Full Text] [Related]

  • 22. Mesothelin-Specific CAR T Cells Target Ovarian Cancer.
    Schoutrop E, El-Serafi I, Poiret T, Zhao Y, Gultekin O, He R, Moyano-Galceran L, Carlson JW, Lehti K, Hassan M, Magalhaes I, Mattsson J.
    Cancer Res; 2021 Jun 01; 81(11):3022-3035. PubMed ID: 33795251
    [Abstract] [Full Text] [Related]

  • 23. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor.
    Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ.
    Mol Ther; 2012 Mar 01; 20(3):633-43. PubMed ID: 22127019
    [Abstract] [Full Text] [Related]

  • 24. CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
    Zeltsman M, Dozier J, McGee E, Ngai D, Adusumilli PS.
    Transl Res; 2017 Sep 01; 187():1-10. PubMed ID: 28502785
    [Abstract] [Full Text] [Related]

  • 25. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy.
    Lee JC, Hayman E, Pegram HJ, Santos E, Heller G, Sadelain M, Brentjens R.
    Cancer Res; 2011 Apr 15; 71(8):2871-81. PubMed ID: 21487038
    [Abstract] [Full Text] [Related]

  • 26. Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.
    Goto S, Sakoda Y, Adachi K, Sekido Y, Yano S, Eto M, Tamada K.
    Cancer Immunol Immunother; 2021 Sep 15; 70(9):2503-2515. PubMed ID: 33559069
    [Abstract] [Full Text] [Related]

  • 27. Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects.
    Zhu Y, Wang K, Yue L, Zuo D, Sheng J, Lan S, Zhao Z, Dong S, Hu S, Chen X, Feng M.
    Pharmacol Res; 2024 May 15; 203():107186. PubMed ID: 38641176
    [Abstract] [Full Text] [Related]

  • 28. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
    Watanabe K, Luo Y, Da T, Guedan S, Ruella M, Scholler J, Keith B, Young RM, Engels B, Sorsa S, Siurala M, Havunen R, Tähtinen S, Hemminki A, June CH.
    JCI Insight; 2018 Apr 05; 3(7):. PubMed ID: 29618658
    [Abstract] [Full Text] [Related]

  • 29. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ.
    Blood; 2012 Jan 19; 119(3):696-706. PubMed ID: 22117050
    [Abstract] [Full Text] [Related]

  • 30. Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model.
    Soltantoyeh T, Akbari B, Shahosseini Z, Mirzaei HR, Hadjati J.
    Front Immunol; 2024 Jan 19; 15():1362904. PubMed ID: 38855110
    [Abstract] [Full Text] [Related]

  • 31. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
    Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS.
    J Clin Invest; 2016 Aug 01; 126(8):3130-44. PubMed ID: 27454297
    [Abstract] [Full Text] [Related]

  • 32. Breaking through the treatment desert of conventional mesothelin-targeted CAR-T cell therapy for malignant mesothelioma: A glimpse into the future.
    Wang Y, Zhao G, Xing S, Wang S, Li N.
    Pharmacol Res; 2024 Jun 01; 204():107220. PubMed ID: 38768670
    [No Abstract] [Full Text] [Related]

  • 33. rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors.
    Li D, Liang T, Hutchins LE, Wolfarth AA, Ferrando-Martinez S, Lee BH, Ho M.
    J Immunother Cancer; 2024 Jul 23; 12(7):. PubMed ID: 39043602
    [Abstract] [Full Text] [Related]

  • 34. NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.
    Xu X, Huang W, Heczey A, Liu D, Guo L, Wood M, Jin J, Courtney AN, Liu B, Di Pierro EJ, Hicks J, Barragan GA, Ngai H, Chen Y, Savoldo B, Dotti G, Metelitsa LS.
    Clin Cancer Res; 2019 Dec 01; 25(23):7126-7138. PubMed ID: 31484667
    [Abstract] [Full Text] [Related]

  • 35. Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
    Zhang Q, Wang H, Li H, Xu J, Tian K, Yang J, Lu Z, Zheng J.
    Oncotarget; 2017 Feb 07; 8(6):9488-9499. PubMed ID: 28055955
    [Abstract] [Full Text] [Related]

  • 36. The exosomes derived from CAR-T cell efficiently target mesothelin and reduce triple-negative breast cancer growth.
    Yang P, Cao X, Cai H, Feng P, Chen X, Zhu Y, Yang Y, An W, Yang Y, Jie J.
    Cell Immunol; 2021 Feb 07; 360():104262. PubMed ID: 33373818
    [Abstract] [Full Text] [Related]

  • 37. CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions.
    Hu W, Zi Z, Jin Y, Li G, Shao K, Cai Q, Ma X, Wei F.
    Cancer Immunol Immunother; 2019 Mar 07; 68(3):365-377. PubMed ID: 30523370
    [Abstract] [Full Text] [Related]

  • 38. Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering.
    Han X, Cinay GE, Zhao Y, Guo Y, Zhang X, Wang P.
    Mol Ther; 2017 Nov 01; 25(11):2466-2476. PubMed ID: 28784559
    [Abstract] [Full Text] [Related]

  • 39. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.
    Proc Natl Acad Sci U S A; 2016 Jan 26; 113(4):E450-8. PubMed ID: 26759368
    [Abstract] [Full Text] [Related]

  • 40. Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
    Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL.
    Mol Ther; 2019 Nov 06; 27(11):1919-1929. PubMed ID: 31420241
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.